This proof-of-concept randomized controlled clinical trial explores the safety, feasibility, and preliminary efficacy of psilocybin-enhanced psychotherapy versus treatment-as-usual among military Veterans being treated for methamphetamine use disorder within a residential treatment facility.

This proof-of-concept clinical trial is the first to explore the safety and feasibility of MDMA-assisted psychotherapy conducted in a group therapy format. Participants will be military Veterans with PTSD.

We conducted a focus group regarding trauma-related mental health experiences among gender diverse individuals in order to inform a more inclusive approach to the development of MDMA-assisted therapy for this marginalized group. We are enrolling a cohort of transgender and gender diverse Veterans into our MDMA-assisted group therapy study.

SNaP Lab is a site for this Phase 3, randomized, double-blind, multicenter study to evaluate the efficacy, safety, and tolerability of psilocybin in adults with Major Depressive Disorder (MDD).

This proof-of-concept randomized controlled clinical trial evaluates the safety and effectiveness of MDMA-assisted therapy for adults with social anxiety disorder.

OPEN is a nascent practice-based research network, designed to assess the safety and equity of psilocybin services in community-based settings and develop a framework for future studies. The OPEN project aims to collect confidential information from licensed psilocybin facilitators and their clients to assess their experience with legal psilocybin services.